Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Erica L Mayer

Showing results (61-70 of 120) with videos related to

Pageof 12
Sort By:
Breast Cancer Research and Treatment|September 25, 2013
Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practiceKathryn J Ruddy, Stephen D Desantis, Rebecca S Gelman, et al.
Cancer Chemotherapy and Pharmacology|February 15, 2021
Phase I study of JAK1/2 inhibitor ruxolitinib with weekly paclitaxel for the treatment of HER2-negative metastatic breast cancerFilipa Lynce, James T Williams, Meredith M Regan, et al.
NPJ Breast Cancer|November 13, 2025
Evolving incidence patterns for locally advanced operable breast cancer by receptor status: SEER 2010-2021Alexandra Thomas, Anthony Rhoads, Erica L Mayer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 9, 2024
Further Optimizing Care of Patients With Operable Hormone Receptor-Sensitive Breast CancerAlexandra Thomas, Erica L Mayer, Angela DeMichele, et al.
Clinical Breast Cancer|June 26, 2019
Ribociclib Plus Trastuzumab in Advanced HER2-Positive Breast Cancer: Results of a Phase 1b/2 TrialShom Goel, Sonia Pernas, Zhenying Tan-Wasielewski, et al.
Breast Cancer Research and Treatment|June 17, 2022
Outcomes after treatment of breast cancer during pregnancy including taxanes and/or granulocyte colony-stimulating factor use: findings from a multi-institutional retrospective analysisTal Sella, Pedro Exman, Siyang Ren, et al.
Breast Cancer Research and Treatment|August 12, 2025
Combined intermittent fasting and exercise intervention in patients with metastatic, hormone receptor-positive breast cancer (FastER): a pilot studyPaola Gonzalo-Encabo, Anita Giobbie-Hurder, Dorothy D Sears, et al.
Cancer|October 11, 2021
Do you mind if I record?: Perceptions and practice regarding patient requests to record clinic visits in oncologyRachel B Jimenez, Andrew E Johnson, Nora K Horick, et al.
Cancer|November 29, 2016
Effect of the LIVESTRONG at the YMCA exercise program on physical activity, fitness, quality of life, and fatigue in cancer survivorsMelinda L Irwin, Brenda Cartmel, Maura Harrigan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 10, 2015
Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance)Hope S Rugo, William T Barry, Alvaro Moreno-Aspitia, et al.
Pageof 12

Showing results (61-70 of 120) with videos related to

Sort By:
Pageof 12
Breast Cancer Research and Treatment|September 25, 2013
Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practiceKathryn J Ruddy, Stephen D Desantis, Rebecca S Gelman, et al.
Cancer Chemotherapy and Pharmacology|February 15, 2021
Phase I study of JAK1/2 inhibitor ruxolitinib with weekly paclitaxel for the treatment of HER2-negative metastatic breast cancerFilipa Lynce, James T Williams, Meredith M Regan, et al.
NPJ Breast Cancer|November 13, 2025
Evolving incidence patterns for locally advanced operable breast cancer by receptor status: SEER 2010-2021Alexandra Thomas, Anthony Rhoads, Erica L Mayer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 9, 2024
Further Optimizing Care of Patients With Operable Hormone Receptor-Sensitive Breast CancerAlexandra Thomas, Erica L Mayer, Angela DeMichele, et al.
Clinical Breast Cancer|June 26, 2019
Ribociclib Plus Trastuzumab in Advanced HER2-Positive Breast Cancer: Results of a Phase 1b/2 TrialShom Goel, Sonia Pernas, Zhenying Tan-Wasielewski, et al.
Breast Cancer Research and Treatment|June 17, 2022
Outcomes after treatment of breast cancer during pregnancy including taxanes and/or granulocyte colony-stimulating factor use: findings from a multi-institutional retrospective analysisTal Sella, Pedro Exman, Siyang Ren, et al.
Breast Cancer Research and Treatment|August 12, 2025
Combined intermittent fasting and exercise intervention in patients with metastatic, hormone receptor-positive breast cancer (FastER): a pilot studyPaola Gonzalo-Encabo, Anita Giobbie-Hurder, Dorothy D Sears, et al.
Cancer|October 11, 2021
Do you mind if I record?: Perceptions and practice regarding patient requests to record clinic visits in oncologyRachel B Jimenez, Andrew E Johnson, Nora K Horick, et al.
Cancer|November 29, 2016
Effect of the LIVESTRONG at the YMCA exercise program on physical activity, fitness, quality of life, and fatigue in cancer survivorsMelinda L Irwin, Brenda Cartmel, Maura Harrigan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 10, 2015
Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance)Hope S Rugo, William T Barry, Alvaro Moreno-Aspitia, et al.
Pageof 12